Catalyst Pharmaceuticals Inc

CPRX is locked in a flat, range-bound structure with overlapping EMAs at the same level and extreme overbought readings; while the medium-term Stage 1 base supports a bullish bias, short-term execution is deferred until a clear pullback into the EMAs.

• ↑19.8% YOY revenue growth to $589M in 2025 driven by Ferdaps and Agamri.
• ↑Cash reserves of $709.2M provide strategic R&D and buyback flexibility.
• ↓Generic FICOMPA entry expected to erode significant revenue.